Related Experiment Video

Updated: Aug 8, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Hypothesis: the antitumor activities of statins may be mediated by IL-18

Hideo Kohka Takahashi, Gabriele Weitz-Schmidt, Hiromi Iwagaki

    Journal of Leukocyte Biology
    |June 1, 2006
    PubMed

    Insights

    Statins may fight cancer by increasing interleukin-18 (IL-18) production. This immune-boosting cytokine is linked to statin

    Area of Science:

    • Biochemistry
    • Immunology
    • Oncology

    Background:

    • Statins inhibit HMG-CoA reductase, impacting Ras farnesylation and lipid levels, potentially reducing cancer risk.
    • Interleukin-18 (IL-18), a cytokine, demonstrates antitumor effects via immune cell activation and anti-angiogenesis.
    • Previous research indicated that certain statins (pravastatin, fluvastatin, simvastatin) stimulate IL-18 production in human monocytes.

    Discussion:

    • Mevalonate addition reversed statin-induced IL-18 production, suggesting a link to HMG-CoA reductase inhibition.
    • This study proposes a novel hypothesis connecting IL-18 production to the anticancer mechanisms of statins.
    • The findings suggest IL-18 may mediate some of the beneficial effects of statins in cancer treatment or prevention.

    Key Insights:

    • Statins, known cholesterol-lowering drugs, may possess anticancer properties.
    • IL-18 production is induced by statins in monocytes, a process dependent on HMG-CoA reductase inhibition.
    • IL-18's role in immune response and angiogenesis inhibition aligns with potential statin anticancer activity.

    Outlook:

    • Further research is warranted to elucidate the precise mechanisms by which IL-18 mediates statin's anticancer effects.
    • Investigating IL-18 levels in patients undergoing statin therapy could provide clinical insights.
    • This hypothesis opens new avenues for exploring statins as adjunct cancer therapies.

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Drugs that Stabilize Microtubules01:15

    Drugs that Stabilize Microtubules

    Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
    Drugs that Destabilize Microtubules01:10

    Drugs that Destabilize Microtubules

    Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...